Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program

Gottlieb, Alice B.; Burge, Russel; Malatestinic, William N; Zhu, Baojin; Zhao, Yang; McCormack, Julie; Kimel, Miriam; Feely, Meghan; Merola, Joseph F.

doi:10.25251/skin.7.supp.201

J of Skin

2023

DOI: 10.25251/skin.7.supp.201

|View full text |Cite

Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program

Alice B. Gottlieb¹,

Russel Burge²,

William N Malatestinic³

et al.

Abstract: BSA) measured by PREPI questionnaire -PREPI: Single question in which the patient estimates how many palms of the hand are needed to cover psoriasis patches on the body -A palm of the patient's hand is ~ 1% BSA ■ Psoriatic arthritis diagnosis is self-reported

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies

Singh

2024

CDTH

View full text Add to dashboard Cite

Psoriasis is a chronic immune-mediated skin disorder affecting millions worldwide. The pathogenesis of psoriasis involves dysregulated immune responses characterized by aberrant activation of T cells and proinflammatory cytokines. Immunomodulation has emerged as a promising therapeutic approach for managing psoriasis, aiming to restore immune homeostasis. However, despite significant advancements, challenges persist in developing effective immunomodulatory therapies. This abstract reviews recent developments in psoriasis immunomodulation, encompassing novel targets and therapeutic modalities. Advances in biologics targeting interleukins (IL) and their receptors, such as IL-17, IL-23, and IL-12/23, have demonstrated substantial clinical efficacy. Additionally, small molecules that inhibit Janus kinases (JAK) and phosphodiesterase 4 (PDE4) have shown promise in regulating immune responses. Despite these advancements, certain limitations hinder the success of immunomodulatory therapies. Treatment resistance, safety concerns, and high costs remain critical challenges. Furthermore, a deeper understanding of the complex immunopathogenesis of psoriasis is essential for developing targeted and personalized therapies. In conclusion, immunomodulation has revolutionized the management of psoriasis, offering remarkable improvements in patient outcomes. Continued research and innovative therapeutic strategies are needed to overcome current challenges and pave the way for more efficient, safe, and accessible treatments for psoriasis.

show abstract

Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies

Singh

2024

CDTH

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program

Abstract: BSA) measured by PREPI questionnaire -PREPI: Single question in which the patient estimates how many palms of the hand are needed to cover psoriasis patches on the body -A palm of the patient's hand is ~ 1% BSA ■ Psoriatic arthritis diagnosis is self-reported

Cited by 1 publication

References 0 publications

Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies

Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies

Contact Info

Product

Resources

About